Business Description
2cureX AB
ISIN : SE0010468124
Compare
Compare
Traded in other countries / regions
2CUREX.Sweden2QE.Germany IPO Date
2017-11-24Description
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency, mainly for cancer patients. It is involved in developing a product, namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and pancreatic cancers. The company's sub-products include IndiTreat Test, IndiTreat clinical programs, and IndiTreat Therapy Design.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.61 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 48.7 | |||||
3-Year EPS without NRI Growth Rate | 46 | |||||
3-Year FCF Growth Rate | 45.3 | |||||
3-Year Book Growth Rate | -64.8 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.63 | |||||
9-Day RSI | 52.81 | |||||
14-Day RSI | 53.74 | |||||
3-1 Month Momentum % | 559.4 | |||||
6-1 Month Momentum % | 473.46 | |||||
12-1 Month Momentum % | 393.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.55 | |||||
Quick Ratio | 2.55 | |||||
Cash Ratio | 1.7 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.8 | |||||
Shareholder Yield % | -3.67 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -26.7 | |||||
ROA % | -17.13 | |||||
3-Year ROIIC % | -1074.34 | |||||
ROC (Joel Greenblatt) % | -135.58 | |||||
ROCE % | -23.87 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 0.55 | |||||
PB Ratio | 19.03 | |||||
Price-to-Tangible-Book | 18.63 | |||||
EV-to-EBIT | -75.16 | |||||
EV-to-Forward-EBIT | -7.96 | |||||
EV-to-EBITDA | -80.81 | |||||
EV-to-Forward-Revenue | 11.06 | |||||
EV-to-FCF | -50.12 | |||||
Price-to-Net-Current-Asset-Value | 18.63 | |||||
Price-to-Net-Cash | 44.25 | |||||
Earnings Yield (Greenblatt) % | -1.32 | |||||
FCF Yield % | -1.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
2cureX AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | |||
EPS (TTM) (kr) | -0.073 | ||
Beta | 0.37 | ||
3-Year Sharpe Ratio | 0.21 | ||
3-Year Sortino Ratio | 0.55 | ||
Volatility % | 254.72 | ||
14-Day RSI | 53.74 | ||
14-Day ATR (kr) | 0.617533 | ||
20-Day SMA (kr) | 3.912 | ||
12-1 Month Momentum % | 393.88 | ||
52-Week Range (kr) | 0.33 - 5.52 | ||
Shares Outstanding (Mil) | 25.1 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
2cureX AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
2cureX AB Stock Events
Event | Date | Price (kr) | ||
---|---|---|---|---|
No Event Data |
2cureX AB Frequently Asked Questions
What is 2cureX AB(OSTO:2CUREX)'s stock price today?
The current price of OSTO:2CUREX is kr3.54. The 52 week high of OSTO:2CUREX is kr5.52 and 52 week low is kr0.33.
When is next earnings date of 2cureX AB(OSTO:2CUREX)?
The next earnings date of 2cureX AB(OSTO:2CUREX) is 2025-07-04 Est..
Does 2cureX AB(OSTO:2CUREX) pay dividends? If so, how much?
2cureX AB(OSTO:2CUREX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |